Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin with a C-terminal Pro-Gly-Pro stabilizing extension, molecular weight 751.87 g/mol. Developed alongside Semax at the Institute of Molecular Genetics, it has been studied for its interactions with the GABAergic system, serotonin transporter expression, and immune-brain axis signaling.
Research has examined Selank in anxiety models (showing comparable effects to benzodiazepines in some studies without sedation or dependence markers), working memory tasks, and inflammatory cytokine modulation in CNS tissue. Its dual nootropic-anxiolytic research profile and demonstrated CNS penetration make it a valuable tool for researchers studying stress-related cognitive impairment.
Each Etched Research vial contains 10mg of lyophilized powder, purity-verified at ≥99% via HPLC and mass spectrometry. Batch-specific Certificate of Analysis included.
Specifications:
– Molecular Formula: C33H57N11O9
– Molecular Weight: 751.87 g/mol
– Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
– Purity: ≥99% (HPLC + Mass Spectrometry)
– Form: Lyophilized powder
– Storage: -20°C (lyophilized); 4°C once reconstituted, use within 30 days
FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION, INGESTION, OR ANY IN VIVO USE.
- What it is: A synthetic 7-amino-acid peptide developed by Russian researchers, based on a natural fragment called tuftsin.
- Researchers have studied it for: anxiety and neurasthenia, nootropic (thinking and focus) effects, and how it acts on the GABA calming system.
- Evidence level: Thin and mostly Russian-language. The human studies are small, and there are no large, independent Western trials confirming them.
- The short version: Most Selank research is small and published in Russian, and the exact pathway is still an open question. The leading idea points at the brain’s GABA calming system. The human case is not settled, and this is a research summary, not a reason to use anything.
Reviews
There are no reviews yet.